regulatory status is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-17. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Alpha-fetoprotein (AFP, α-fetoprotein; also sometimes called alpha-1-fetoprotein, alpha-fetoglobulin, or alpha fetal protein) is a protein that in humans is encoded by the AFP gene. The AFP gene is located on the q arm of chromosome 4 (4q13.3). Maternal AFP serum level is used to screen for Down syndrome, neural tube defects, and other chromosomal abnormalities. AFP is a major plasma protein produced by the yolk sac and the fetal liver during fetal development. It is thought to be the fetal analog of serum albumin. AFP binds to copper, nickel, fatty acids and bilirubin and is found in monomeric, dimeric and trimeric forms.
bacterial and mitochondrial N-formyl peptides and thereby initiates innate host immune responses. various synthetic N-formyl and non-formylated peptides that show distinguishing differences from those that interact with FPR2 and FPR3. T20/DP178 & T21/DP107, N-acetylated polypeptides derived from the gp41 HIV-1 envelope protein. This interaction is of unknown physiological significance although peptide T20/DP178 is a licensed anti-retrovirus agent (pentafuside) termed Enfuvirtide which acts at the level of HIV-target cell fusion and is used clinically to treat HIV-1 infection). Annexin A1 (also termed ANXA1 and lipocortin 1) and its N-terminal peptides (Ac2–26 and Ac9–25). At low concentrations, these agents stimulate neutrophils to raise cytosolic Ca2+ levels and thereby activate Ca2+-dependent signaling pathways; however, they do not fully activate the MAPK pathway but rather leave the neutrophil desensitized (i.e. unresponsive) to chemokine IL-8. At high concentrations, in contrast, the agents fully activate neutrophils and are potent pro-inflammatory stimulants.
== Sequential and discrete models == Two kinds of models are usually used to represent protein samples: the sequential and the discrete (or non-sequential) models. The most elementary sequential model is to use the entire amino acid sequence, as expressed by:
Crick was aware that research on consciousness was a difficult task, as he wrote to Martynas Yčas in April 1996:I don't think we shall fully understand consciousness by the end of this century, but it's possible we can get a glimpse of the answer by then. Whether it will all fall into place, as molecular biology did, without a vital force, or whether we need a radical formulation, only time will tell. Best wishes, Yours, Francis. P.S. By the way, I've not been knighted.
Sources: en.wikipedia.org
=== Reverse CAMP === The reverse CAMP test utilizes the synergetic hemolytic abilities of the CAMP factor produced by Streptococcus agalactiae with the α-toxin produced by Clostridium perfringens. Streaking these two organisms perpendicular to each other on a blood agar plate will yield a "bow-tie" clearing of the blood agar by the hemolytic capabilities of the two organisms' toxins. Incubation requires 24 hours at 37 °C.
However, the mobilization against the "peace process", as its defenders called it, did not prevent the government from initiating contacts with the ETA leadership. To put pressure on the government, ETA intensified street fighting (kale borroka) and finally on December 30, 2006, T-4 bombing placed a powerful bomb in the T-4 terminal of Barajas airport which caused the death of two people and enormous material damage. The government considered the "peace process" "suspended" and on June 4, ETA announced the end of the truce. Attacks were resumed and members of ETA and Batasuna were arrested. Likewise, the process of illegalization of the Communist Party of the Basque Homelands and Basque Nationalist Action began. In response ETA murdered in cold blood a former socialist councilman in the Gipuzkoan town of Mondragón on the eve of the March 2008 general election.
Staphylococci are considered to have a creamy consistency, while some Neisseria species are sticky, and colonies of diphtheroid bacteria and beta-hemolytic streptococci are typically dry. Bacteria that produce capsules often have a slimy (mucoid) consistency. When certain microorganisms are grown on blood agar, they may digest the blood in the medium, causing visible hemolysis (destruction of red blood cells) on the agar plate. In colonial morphology, hemolysis is classified into three types: alpha-, beta-, and gamma-hemolysis. In alpha-hemolysis, the blood is partially digested, causing the area around the colony to turn green. In beta-hemolysis, the organism digests the blood completely, leaving a clear area around each colony. Organisms that do not produce hemolysis are referred to as gamma-hemolytic. Clostridium perfringens, which causes gas gangrene, is noteworthy for producing a "double zone" of both complete and incomplete hemolysis. The odour of a culture is sometimes considered part of colonial morphology. While intentionally smelling microbial cultures is not advised, some organisms produce distinctive odours that can be detected during routine examination of the culture. Among these are Pseudomonas aeruginosa, which has a grape-like scent; Staphylococcus aureus, which is said to smell like old socks; and Proteus mirabilis, whose scent is alternately described as putrid or like chocolate cake. Other distinctive features of colonial morphology include motility and the production of pigments.
Sources: en.wikipedia.org
March 26 COVID-19 pandemic Maine reports its first case of the Lineage P.1 variant, which was originally detected in Brazil. Wisconsin confirms their first cases of the Lineage P.1 and 501.V2 variants of SARS-CoV-2. Arizona reports its first case of the 501.V2 variant, which was originally detected in South Africa. New Jersey amends its alcohol and cannabis laws to allow police to notify parents or guardians after a first-time offense by a minor, following strong opposition to the prohibition on first-time notifications implemented when New Jersey legalized cannabis the previous month. The U.S. Food and Drug Administration (FDA) approves Abecma to treat multiple myeloma. Abecma is the first cell-based gene therapy approved by the FDA for the treatment of multiple myeloma. March 29 In Minnesota, opening statements begin at the trial of former police officer Derek Chauvin, who is accused of murdering 46-year-old black man George Floyd by kneeling on his neck. The Arkansas Senate passed, HB1570, a bill that prohibited normally functioning and physically healthy minors from puberty blockers, cross-sex hormones, and genital and non-genital invasive surgical alterations. A judge orders three men charged with plotting to kidnap Michigan Governor Gretchen Whitmer to stand trial, after a three-day preliminary hearing. Threat of terrorism charges are also dismissed against two of the defendants. Killing of Adam Toledo – A 13-year-old Latino boy, Adam Toledo, is shot and killed by an officer of the Chicago Police Department.
==== Silver alloy – synergistic oxidation of carbon monoxide ==== Au-Ag alloy nanoparticles have been shown to have a synergistic effect on the oxidation of carbon monoxide (CO). On its own, each pure-metal nanoparticle shows very poor catalytic activity for CO oxidation; together, the catalytic properties are greatly enhanced. It is proposed that the gold acts as a strong binding agent for the oxygen atom and the silver serves as a strong oxidizing catalyst, although the exact mechanism is still not completely understood. When synthesized in an Au/Ag ratio from 3:1 to 10:1, the alloyed nanoparticles showed complete conversion when 1% CO was fed in air at ambient temperature. The size of the alloyed particles did not play a big role in the catalytic ability. It is well known that gold nanoparticles only show catalytic properties for CO when they are ~3 nm in size, but alloyed particles up to 30 nm demonstrated excellent catalytic activity – catalytic activity better than that of gold nanoparticles on active support such as TiO2, Fe2O3, etc.
The first suborbital spacecraft weighed 3,000 pounds (1,400 kg); the heaviest, Mercury-Atlas 9, weighed 3,000 pounds (1,400 kg) fully loaded. On reentry, the astronaut would stay in the craft through splashdown by parachute in the Atlantic Ocean.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.